3,4-二甲氧基-5-羟基苯甲酸甲酯 | 83011-43-2

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-二甲氧基-5-羟基苯甲酸甲酯
• 中文别名: 3,4-二甲氧基-5-羟基苯甲酸盐；3,4-二甲氧基-5-羟基苯甲 酸 甲基 酯
• 英文名称: 3-hydroxy-4,5-dimethoxybenzoate
• 英文别名: methyl 3-hydroxy-4,5-dimethoxybenzoate
• CAS: 83011-43-2
• 化学式: C₁₀H₁₂O₅
• mdl: MFCD00598192
• 分子量: 212.202
• InChiKey: LCIFXEQPXQVBGL-UHFFFAOYSA-N

物化性质

• 熔点：
  80-84 °C
• 沸点：
  312.03°C (rough estimate)
• 密度：
  1.3006 (rough estimate)
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.36
• 重原子数：
  15.0
• 可旋转键数：
  4.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  64.99
• 氢给体数：
  1.0
• 氢受体数：
  4.0

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放在阴凉干燥处即可。

SDS

Name:	Methyl 4 5-Dimethoxy-3-Hydroxybenzoate 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	83011-43-2

Section 1 - Chemical Product MSDS Name:Methyl 4 5-Dimethoxy-3-Hydroxybenzoate 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
83011-43-2	Methyl 4,5-Dimethoxy-3-Hydroxybenzoate	98	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 83011-43-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white
Odor: odorless
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 81-83 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H12O5
Molecular Weight: 212.081

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 83011-43-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 4,5-Dimethoxy-3-Hydroxybenzoate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 83011-43-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 83011-43-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 83011-43-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

产品描述

3,4-二甲氧基-5-羟基苯甲酸甲酯是一种酯类衍生物，作为合成阿考替胺的重要中间体。盐酸阿考替胺是由日本Zeria新药工业株式会社研发的一种新型M1、M2受体拮抗剂，并被批准用于治疗功能性消化不良引起的餐后饱胀和上腹胀。

产品用途

3,4-二甲氧基-5-羟基苯甲酸甲酯可用作医药中间体，是合成阿考替胺的关键原料。

反应信息

• 作为反应物：
  描述：

  3,4-二甲氧基-5-羟基苯甲酸甲酯 在 溴 、 铜 作用下， 反应 10.08h， 生成 trimethylocta-O-methylvalonate
  参考文献：
  名称：

  Tannins and related compounds. XCVI. Structures of macaranins and macarinins, new hydrolyzable tannins possessing macaranoyl and tergalloyl ester groups, from the leaves of Macaranga sinensis (Baill.) Muell.-Arg.

  摘要：

  与已知的十一种化合物（1-11）一起，从Macaranga sinensis (BAILL.) MUELL.-ARG.（大戟科）的叶子中分离出了七种新单宁，分别为3-desgalloylterchebin（12）、macaranins A、B和C。根据化学和光谱证据，确定macaranins A（14）、B（13）和C（17）为可水解的单宁，具有在1C4（或倾斜船型）β-D-葡萄糖环的3、6位上的新型酰基（macaranoly基团），而macarinins A（18）、B（15）和C（16）被鉴定为在相同位置具有tergalloyl基团的化合物。

  DOI：

  10.1248/cpb.38.1844
• 作为产物：
  描述：

  没食子酸 在 硫酸 作用下， 生成 3,4-二甲氧基-5-羟基苯甲酸甲酯
  参考文献：
  名称：

  异黄酮的合成。第五部分Irigenin和Tectorigenin

  摘要：

  合成异黄酮的一般乙氧基化方法已应用于合成irigenin（VII）和tectorigenin（XVI）。该合成途径也产生了异构体，ψ -irigenin（XI）和ψ -tectorigenin（XX）。讨论了有关某些乙氧基化反应中产物比例以及5,6,7-和5,7,8-三取代异黄酮的相对热力学稳定性的信息。

  DOI：

  10.1039/j39700001219

文献信息

• Ruthenium-Catalyzed Hydroarylation and One-Pot Twofold Unsymmetrical C−H Functionalization of Arenes
  作者：Koushik Ghosh、Raja K. Rit、E. Ramesh、Akhila K. Sahoo

  DOI：10.1002/anie.201600649

  日期：2016.6.27

  excellent yields. A one‐pot, unsymmetrical, twofold C−H functionalization involving intramolecular C−C and intermolecular C−C/C−N bond formations is successfully demonstrated by using a single set of catalytic reaction conditions, which is unprecedented thus far. A novel isoquinolone‐bearing dihydrobenzofuran is constructed through an unsymmetrical twofold C−H functionalization.

  甲基苯基硫肟亚胺（MPS）用作链烯基苯甲酸衍生物在钌催化的分子内氢芳基化反应中的导向基团，从而以良好或优异的收率提供二氢苯并呋喃和二氢吲哚。通过使用一组催化反应条件成功地证明了涉及分子内C-C和分子间C-C / C-N键形成的单锅，不对称，双重CH功能化，这是迄今为止前所未有的。通过不对称的双重CH官能团构建了一种新型的带有异喹诺酮的二氢苯并呋喃。
• New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa
  申请人：——

  公开号：US20020198195A1

  公开（公告）日：2002-12-26

  The present invention relates to compounds comprising the following formula: R 0 —Q—X—Q′—W—U—V—G—M  (I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.

  本发明涉及包含以下公式的化合物： R 0 —Q—X—Q′—W—U—V—G—M  (I) 这些化合物作为药物活性化合物是有用的。它们展现出抗血栓作用，并适用于例如治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。这些化合物是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆性抑制剂，通常可用于治疗、预防或治愈存在因子Xa和/或因子VIIa不期望活性的情况，或旨在抑制因子Xa和/或因子VIIa的情况。本发明还涉及制备这些化合物的方法、它们的使用方法（例如，作为药品中的活性成分）以及包含它们的药物制剂。
• Synthesis and biological evaluation of phenstatin metabolites
  作者：Alina Ghinet、Benoît Rigo、Jean-Pierre Hénichart、Delphine Le Broc-Ryckewaert、Jean Pommery、Nicole Pommery、Xavier Thuru、Bruno Quesnel、Philippe Gautret

  DOI：10.1016/j.bmc.2011.08.047

  日期：2011.10

  metabolites. The structures of eight of these metabolites have been now confirmed by synthesis and their biological properties have been reported. Eaton’s reagent was utilized as a convenient condensing agent, allowing, among others, a simple multigram scale preparation of phenstatin. Synthesized metabolites and related compounds were evaluated for their antiproliferative activity in the NCI-60 cancer cell

  以前对非那他汀与大鼠和人类微粒体组分温育的研究表明形成了九种主要代谢产物。现在已经通过合成确认了其中8种代谢物的结构，并报道了它们的生物学特性。伊顿的试剂被用作便利的缩合剂，除其他外，还可以简单地制得数克规模的芬他汀。评价了合成代谢产物和相关化合物在NCI-60癌细胞系中的抗增殖活性，以及​​它们对微管组装的影响。代谢物23（2'-甲氧吩他汀）表现出最有效的体外细胞毒性活性：抑制K-562，NCI-H322M，NCI-H522，KM12，M14，MDA-MB-435，NCI / ADR-RES，和带有GI的HS 578T细胞系50个值<10 nM。它也显示出比亲本芬他汀（3）更显着的微管蛋白聚合抑制活性（IC 50  = 3.2μM对15.0μM ），并在鼠白血病DA1-3b细胞中诱导G2 / M阻滞。对这种活性代谢产物的鉴定导致了具有强大的体外细胞毒性和抑制微管组装的类似物的设计和合成。
• Alkylenediamine derivative anti-ulcer drug and antibacterial drug
  申请人：Shiseido Co. Ltd.

  公开号：US05814634A1

  公开（公告）日：1998-09-29

  The invention provides a compound which has anti-ulcer effect and antibacterial activity against Helicobacter pyroli. This compound is an alkylenediamine derivative or salt which has a general formula of (1): ##STR1## wherein each of R.sub.4, R.sub.5, and R.sub.6 is hydrogen or lower alkyl; n represents an integer of 1 to 6; Y is --CH.sub.2 --, --O--, or --N(R.sub.7)--, wherein R.sub.7 is lower alkyl, aryl, carbamoyl lower alkyl, aralkyl, or a heterocyclic group having 5 to 9 carbon numbers; and, W is a group expressed by formulas 2 or 3: ##STR2## wherein (1) in formula 2: each of R.sub.1 and R.sub.2 is hydrogen, lower alkoxy, alkenyloxy, or a halogen atom; each of R.sub.3 and R.sub.3 is methyl, prenyl, or geranyl; when one of R.sub.3 and R.sub.3 is prenyl or geranyl, the other must be a methyl group; and X is oxygen or sulfur; and (2) in formula 3, R.sub.10 is a lower alkyl, and R.sub.11 is a halogen atom.

  该发明提供了一种具有抗溃疡作用和抗幽门螺杆菌活性的化合物。该化合物是一种烷二胺衍生物或盐，其具有通式(1)：##STR1## 其中R.sub.4、R.sub.5和R.sub.6中的每一个是氢或较低的烷基；n表示1到6的整数；Y为--CH.sub.2 --、--O--或--N(R.sub.7)--，其中R.sub.7为较低的烷基、芳基、氨基甲酰较低的烷基、芳基烷基或具有5到9个碳原子的杂环基；W为由式2或3表示的基团：##STR2## 其中在式2中：R.sub.1和R.sub.2中的每一个是氢、较低的烷氧基、烯氧基或卤原子；R.sub.3和R.sub.3中的每一个是甲基、异戊烯基或戊二烯基；当R.sub.3和R.sub.3中的一个是异戊烯基或戊二烯基时，另一个必须是甲基；X为氧或硫；在式3中，R.sub.10为较低的烷基，R.sub.11为卤原子。
• Pyrrolidine derivative, anti-ulcer drug, and antibacterial drug
  申请人：Shiseido Co., Ltd.

  公开号：US05925667A1

  公开（公告）日：1999-07-20

  A pyrrolidine derivative or a salt thereof expressed by the following formula 1: ##STR1## wherein R.sub.1 is an alkenyl group; R.sub.2 is a lower alkoxy group or a halogen atom; R.sub.3 is a lower alkyl group; X is a group expressed by --O-- or --S--; Y is carbon or nitrogen atom; m is an integer of 1 to 3; and n is an integer of 0 to 2. The pyrrolidine derivative has an anti-ulcer effect or an antibacterial activity against Helicobacter pyroli, and has also high safety to be available for prevention or cure of ulcers.

  以下是公式1表示的吡咯烷衍生物或其盐：其中R.sub.1是烯基基团；R.sub.2是较低的烷氧基团或卤素原子；R.sub.3是较低的烷基团；X是由--O--或--S--表示的基团；Y是碳或氮原子；m是1到3的整数；n是0到2的整数。该吡咯烷衍生物具有抗溃疡作用或对幽门螺杆菌的抗菌活性，并且对于预防或治疗溃疡具有高度安全性。